Noninvasive biomarkers for lung cancer diagnosis, where do we stand?

J Thorac Dis 2020 Jun;12(6):3317-3330

Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

The 2010's saw demonstration of the power of lung cancer screening to reduce mortality. However, with implementation of lung cancer screening comes the challenge of diagnosing millions of lung nodules every year. When compared to other cancers with widespread screening strategies (breast, colorectal, cervical, prostate, and skin), obtaining a lung nodule tissue biopsy to confirm a positive screening test remains associated with higher morbidity and cost. Therefore, non-invasive diagnostic biomarkers may have a unique opportunity in lung cancer to greatly improve the management of patients at risk. This review covers recent advances in the field of liquid biomarkers and computed tomographic imaging features, with special attention to new methods for combination of biomarkers as well as the use of artificial intelligence for the discrimination of benign from malignant nodules.

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-2019-ndt-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330751PMC
June 2020

Publication Analysis

Top Keywords

lung cancer
16
cancer screening
8
lung
6
diagnostic biomarkers
4
non-invasive diagnostic
4
cost non-invasive
4
morbidity cost
4
biomarkers unique
4
opportunity lung
4
improve management
4
greatly improve
4
cancer greatly
4
higher morbidity
4
unique opportunity
4
remains associated
4
lung nodule
4
nodule tissue
4
obtaining lung
4
skin obtaining
4
prostate skin
4

Similar Publications